Related by context. All words. (Click for frequent words.) 75 androgen independent 74 metastatic castration resistant 74 metastatic castrate resistant 73 prostate cancer CRPC 72 castration resistant prostate cancer 72 CYT# potent vascular disrupting 72 dasatinib Sprycel ® 71 receptor tyrosine kinase inhibitor 71 stage IIIB 71 metastatic hormone refractory 71 CTAP# Capsules 71 metastatic colorectal 71 dasatinib Sprycel 71 recurrent glioblastoma multiforme 71 LHRH receptor positive 71 erlotinib Tarceva ® 71 diarrhea predominant irritable 70 prostate cancer HRPC 70 BCG refractory carcinoma 70 cell lymphoma CTCL 70 familial amyloidotic polyneuropathy FAP 70 advanced metastatic renal 70 mRCC 70 oral prodrug 70 Aflibercept 70 metastatic renal cell carcinoma 70 luteinizing hormone releasing 70 selective modulator 70 imatinib Gleevec ® 70 prostate cancer AIPC 70 HER2 positive metastatic breast 70 Personalized Immunotherapy 70 pan HDAC inhibitor 70 Cutaneous T 69 metastatic androgen independent 69 antibody MAb 69 vinca alkaloid 69 gefitinib Iressa 69 novel VDA molecule 69 delivers fluocinolone acetonide FA 69 CCR9 antagonist 69 biliary tract cancer 69 evaluating picoplatin 69 CCX# B 69 AAG geldanamycin analog 69 acetonide FA 69 PNP inhibitor 69 refractory prostate cancer 69 metaglidasen 69 recurrent NSCLC 69 Vicinium TM 69 Gleevec resistant 69 sodium glucose cotransporter 69 MKC# MT 69 kidney urologic 69 prostate carcinoma 69 GW# [003] 69 Solazed TM 69 evaluating tivozanib 69 Archexin 69 cutaneous T 69 Advanced Renal Cell 69 FOLOTYN ® 69 hormone refractory prostate cancer 69 ovarian carcinoma 69 leukemia AML 68 orally inhaled migraine 68 relapsed MM 68 M2 subunit 68 refractory gout 68 lymphoid malignancies 68 orally administered inhibitor 68 unresectable stage 68 MAGE A3 ASCI 68 bevacizumab Avastin ® 68 phase IIb clinical 68 Bezielle 68 oropharyngeal candidiasis OPC 68 Elagolix 68 Hsp# Inhibitor 68 taxane resistant 68 selective kinase inhibitor 68 hyperplasia BPH 68 virus HCV protease inhibitor 68 IMiDs ® compound 68 relapsed multiple myeloma 68 lintuzumab SGN 68 investigational monoclonal antibody 68 HGS ETR1 mapatumumab 68 alvespimycin 68 atypical Hemolytic Uremic Syndrome 68 HuLuc# 68 IMiDs ® 68 undergoing androgen deprivation 68 modified glutathione analog 68 PRTX 68 thetreatment 68 hormone refractory 68 investigational immunotherapy 68 IMA# 68 metastatic gastric 68 Apoptone 68 toenail onychomycosis 68 situ CIS 68 Motesanib 68 liposomal formulation 68 histone deacetylase HDAC inhibitor 68 Panzem R 68 alkylating agent 68 Peginterferon alfa 2b 68 demonstrated antitumor activity 68 Ophena TM 68 Tyrima 68 nucleoside analog 68 Silodosin 68 Cetrorelix 68 refractory cutaneous T 68 refractory chronic lymphocytic 68 relapsing remitting MS RRMS 68 imatinib Gleevec 67 vidofludimus 67 hyperphenylalaninemia HPA due 67 multiple myeloma MM 67 symptomatic BPH 67 refractory metastatic 67 opioid induced constipation OIC 67 LHRH agonist 67 oral kinase inhibitor 67 heavily pretreated 67 essential thrombocythemia ET 67 superficial bladder cancer 67 non alcoholic steatohepatitis 67 p# biomarker 67 CBLC# 67 HGS ETR1 67 interferon gamma 1b 67 epithelial tumors 67 ACTEMRA TM 67 sorafenib tablets 67 secondary hyperparathyroidism 67 systemic lupus erythematosus SLE 67 PEGylated Fab fragment 67 targeted radiotherapeutic 67 gastrointestinal stromal tumors GIST 67 AEGR 67 induced macular edema 67 PKC# 67 PEGylated anti 67 BRIM2 67 docetaxel Taxotere R 67 resistant hormone refractory 67 BCG refractory 67 Degarelix 67 Cannabinor 67 Familial Adenomatous Polyposis FAP 67 R Saizen R 67 forodesine 67 receptor inhibitor 67 Bosutinib 67 sorafenib Nexavar 67 D aspartate NMDA receptor 67 TNF Tumor Necrosis Factor 67 stage IIIb IV 67 Factor Receptor 67 Cloretazine 67 Epratuzumab 67 ALN PCS 67 metastatic malignant 67 Dasatinib 67 acyclovir Lauriad R 67 metastatic renal cell 67 idiopathic myelofibrosis 67 HGS ETR2 67 radiation sensitizer 67 ALN TTR 67 castrate resistant 67 cMET 67 SUPPRELIN R LA 67 cutaneous T cell 67 mapatumumab 67 Vidofludimus 67 K ras mutations 67 systemic anaplastic large 67 IMiDs R 67 endocrine therapies 67 Pralatrexate 67 PROVENGE sipuleucel T 67 nilotinib Tasigna ® 67 visilizumab 67 tanespimycin 67 metastatic GIST 67 noninfectious uveitis 67 Phase #b/#a clinical 67 Ceflatonin 67 VEGFR2 inhibitor 67 assessing T DM1 67 leukemia CLL 67 Aurora Kinase 67 Meets Primary Endpoint 66 Sudhir Agrawal D.Phil 66 myelodysplastic myeloproliferative diseases 66 colorectal carcinoma 66 LymphoStat B belimumab 66 pancreatic adenocarcinoma 66 Ozarelix 66 non splenectomized 66 systemic fungal infections 66 Belimumab 66 refractory colorectal cancer 66 myelofibrosis polycythemia vera 66 herpetic keratitis 66 oral picoplatin 66 MKC# MKC# PP 66 systemic RNAi therapeutic 66 Hormone Refractory Prostate Cancer 66 formerly LymphoStat B 66 KRN# 66 Relapsed Refractory 66 Sapacitabine 66 Capesaris 66 Traficet EN 66 YONDELIS 66 Omacetaxine 66 erlotinib Tarceva R 66 pan histone deacetylase 66 cetuximab Erbitux R 66 Onalta ™ 66 poly ADP ribose polymerase 66 multi kinase inhibitor 66 SinuNase TM 66 goserelin 66 mu opioid receptor antagonist 66 Blinatumomab 66 JAK inhibitors 66 relapsed leukemia 66 lymphoma CTCL 66 EGFR HER2 66 indinavir Crixivan 66 lexidronam injection 66 docetaxel Taxotere ® 66 trastuzumab Herceptin ® 66 CIMZIA TM certolizumab pegol 66 localized renal 66 EGFR tyrosine kinase inhibitors 66 prostate cancer CaP 66 investigational humanized monoclonal antibody 66 gastrointestinal stromal tumors 66 pertuzumab 66 Fludara ® 66 metastatic colorectal carcinoma 66 Trial Evaluating 66 autologous cellular immunotherapy 66 Proxinium TM 66 Zoraxel 66 trastuzumab Herceptin R 66 humanised monoclonal antibody 66 HRPC 66 Intravenous CP 66 metastatic carcinoid 66 metastatic neuroendocrine tumors 66 oral deforolimus 66 recurrent glioblastoma 66 PSMA ADC 66 custirsen 66 Epidermal Growth Factor Receptor 66 adalimumab Humira 66 advanced metastatic prostate 66 Daclizumab 66 Clolar ® 66 HBeAg negative 66 eosinophilic asthma 66 proliferator activated receptor 66 cilengitide 66 Hsp# inhibition 66 mCRPC 66 Genasense ® 66 TTR amyloidosis 66 treat benign prostatic 66 Insegia 66 PI3K/Akt pathway inhibitor 66 adecatumumab 66 AA Amyloidosis 66 Irinotecan 66 ErbB2 positive 66 Rheumatoid Arthritis RA 66 beta 1a 66 chronic HCV infection 66 volociximab 66 myeloproliferative disorders 66 Vidaza azacitidine 66 humanized anti 66 skeletal metastases 66 androgen receptor antagonist 66 Atypical Hemolytic Uremic Syndrome 66 Romidepsin 66 5 HT6 receptor 66 non metastatic osteosarcoma 66 protein tyrosine phosphatase 1B 66 unresectable tumors 66 Elotuzumab 66 multicenter Phase II 66 castration resistant 66 Kit CD# positive 66 prostate cancer mCRPC 66 schizophrenia CIAS 66 chronic myeloid 66 paclitaxel Taxol 66 interferon beta 1a infertility 66 VitiGam 66 Adjuvant Treatment 66 IgG1 monoclonal antibody 66 proteasome inhibitor 66 targeting CD# 66 RhuDex ® 66 tumors GIST 66 FUSILEV enhances 66 AKT inhibitor 66 hormone LHRH antagonist 66 relapsed ovarian cancer 65 completely resected 65 paclitaxel poliglumex 65 multicenter Phase III 65 PDX pralatrexate 65 HSP# inhibitor 65 antiangiogenic therapy 65 INCB# [003] 65 painful diabetic neuropathy 65 PEGylated interferon beta 1a 65 Talabostat 65 BENLYSTA TM 65 oral nucleoside analogue 65 Luteinizing Hormone Releasing Hormone 65 sunitinib Sutent ® 65 Zorbtive TM 65 Oral Fingolimod 65 Enzastaurin 65 relapsed refractory multiple myeloma 65 novel histone deacetylase 65 sapacitabine CYC# 65 refractory acute myeloid 65 depsipeptide 65 Diffuse Large B 65 hypoxia activated prodrug 65 Panzem R NCD 65 sapropterin dihydrochloride Tablets 65 Hodgkin lymphoma HL 65 Golimumab 65 mTOR mammalian target 65 Malignant Melanoma 65 ospemifene 65 AVASTIN 65 NeoLipid R 65 Diabetic Macular Edema DME 65 Phase Ib clinical trials 65 Nilotinib 65 Temsirolimus 65 metastatic CRPC 65 ritonavir boosted 65 Virulizin ® 65 metastatic RCC 65 sunitinib malate 65 Diabetic Macular Edema 65 soluble tumor necrosis 65 ALK inhibitor 65 lumiliximab 65 Amrubicin 65 differentiated thyroid 65 Microplasmin 65 5 fluorouracil leucovorin 65 dexamethasone Decadron 65 antibody MT# 65 neovascular diseases 65 ELACYT 65 grade cervical intraepithelial 65 LHRH antagonist 65 Phase 2a Clinical Trial 65 OMP #R# 65 Nexavar sorafenib 65 PD LID 65 Safinamide 65 TACI Ig 65 PDE4 inhibitor 65 investigational oral inhibitor 65 Hedgehog Pathway Inhibitor 65 BAY #-# 65 CEQ# 65 hepatitis C HCV 65 Benign Prostatic Hyperplasia BPH 65 idiopathic pulmonary fibrosis IPF 65 JAK inhibitor 65 Fibrillex TM 65 previously untreated follicular 65 Opterone R 65 DU #b 65 HCV protease 65 PSN# [002] 65 Vidaza ® 65 huC# DM4 65 MOVIPREP R 65 iobenguane 65 generation purine nucleoside 65 brand ciclesonide HFA 65 R sorafenib tablets 65 immunotherapeutic agent 65 Glufosfamide 65 reversible inhibitor 65 rheumatoid arthritis psoriatic arthritis 65 IgG1 antibody 65 phase IIa clinical 65 dihydrochloride Tablets 65 rALLy clinical trial 65 MTP inhibitor 65 lomitapide 65 occlusion PAO 65 sunitinib Sutent 65 testosterone buccal system 65 APOPTONE 65 CYP#A# CYP#D# 65 somatostatin analogue 65 interleukin IL -# 65 oncolytic virus therapies 65 R lenalidomide 65 Lubiprostone 65 Aplidin 65 T#I [002] 65 MGd 65 onset idiopathic hypogonadism 65 metastatic pancreatic 65 Metastatic Prostate Cancer 65 CD3 monoclonal antibody 65 Combination REOLYSIN R 65 BCR ABL inhibitor 65 INSPIRE Trial Phase III 65 polycythemia vera essential thrombocythemia 65 chronic eosinophilic leukemia 65 BENICAR HCT 65 Factor VIIa 65 evaluating T DM1 65 L BLP# 65 constipation OIC 65 unresectable locally advanced 65 Achieves Primary Endpoint 65 metastatic bladder 65 intranasal formulation 65 Cloretazine R 65 Plicera 65 somatostatin analog 65 galiximab 65 prostate pancreatic 65 hepatocellular cancer 65 metastatic renal 65 refractory AML 65 Pirfenidone 65 basal cell carcinoma BCC 65 Vascugel 65 IRX 2 65 Crohn disease CD 65 OncoVEX GM CSF 65 refractory NSCLC 65 Solazed ™ 65 FOLFOX6 65 primary immunodeficiency PI 65 Anti VEGF 65 CCX# 65 Phase 2b Clinical Trial 65 humanized interleukin 6 65 recurrent ovarian cancer 65 metastatic malignant melanoma 65 Prolongs Survival 65 Castration Resistant Prostate Cancer 65 anti EGFR antibody 65 ACAPODENE TM 65 erythematosus 65 JAK1 65 candidates Azedra TM 65 ancrod 65 Methylnaltrexone 65 Romiplostim 65 fosbretabulin 65 estramustine 65 delta isoform 65 benign prostatic hypertrophy BPH 65 syngeneic 65 Pemetrexed 65 Evoltra ® 65 polymerase inhibitor 65 Dendreon investigational 65 AVAPRO 65 ALN HPN 65 glucocorticoid induced osteoporosis 65 pathophysiological effects 65 cetuximab Erbitux ® 65 acute coronary syndromes ACS 64 Pertuzumab 64 Cloretazine ® 64 Apaziquone 64 registrational trial 64 Patients Treated With 64 riociguat 64 minimally symptomatic 64 CD# monoclonal antibody 64 severe hypercholesterolemia 64 nonmetastatic 64 Pivotal Phase 64 Azedra 64 Novel Oral 64 cisplatin gemcitabine 64 omega interferon 64 CCR5 antagonist 64 elotuzumab 64 Myelodysplastic Syndrome MDS 64 recurrent malignant glioma 64 erlotinib Tarceva 64 asymptomatic metastatic 64 Serostim R 64 pheochromocytoma 64 plus prednisone 64 NS5b 64 EOquin 64 KRAS mutations occur 64 HCV NS5B polymerase 64 personalized cellular immunotherapy 64 Abiraterone acetate 64 selective antagonist 64 PRT# 64 fistulizing Crohn disease 64 CINQUIL 64 VELCADE melphalan 64 Mitoxantrone 64 SCH # 64 refractory metastatic colorectal cancer 64 Enzyme Replacement Therapy 64 ALK inhibitors 64 TELINTRA 64 ocular formulation 64 peripherally acting 64 irinotecan doxorubicin oxaliplatin paclitaxel 64 Surgical resection 64 KRAS mutant 64 EndoTAG TM -1 64 ovarian breast 64 sodium thiosulfate STS 64 oral dihydropyrimidine dehydrogenase DPD 64 MEK inhibitors 64 chimeric monoclonal antibody 64 AQ4N 64 Tasimelteon 64 gemcitabine Gemzar ® 64 R sipuleucel T 64 subependymal giant cell 64 Dupuytren Disease 64 Ceflatonin R 64 Myelofibrosis 64 MCSP respectively 64 NS#/#A protease 64 hypereosinophilic syndrome 64 ZACTIMA 64 EGFr 64 IAP inhibitor 64 Randomized Phase 64 HQK 64 Certolizumab pegol 64 Hepatocellular Carcinoma HCC 64 malignant ascites 64 PANVAC VF 64 Smac mimetics 64 inhibitor RG# 64 Kinase Inhibitor 64 refractory indolent non 64 highly selective endothelin 64 fallopian tube carcinoma 64 thalidomide Thalomid 64 pancreatic carcinoma 64 SPRYCEL ® 64 CA4P 64 anti angiogenic therapy 64 AEG# 64 prokinetic agent 64 Anturol TM 64 irreversible inhibitor 64 Cerebril TM 64 Orally administered 64 mTOR inhibitor 64 5 FU leucovorin 64 ribonucleotide reductase clinically validated 64 Completes Patient Enrollment 64 orally bioavailable 64 5 HT2A inverse 64 aurora kinase 64 J Am Coll 64 OMNARIS HFA 64 alfa 2a 64 oral Hsp# inhibitor 64 selective immunoproteasome inhibitor 64 Pagoclone 64 Triapine 64 HDAC Inhibitor 64 PDE# 64 pediatric Crohn disease 64 ALN TTR# 64 R metformin Concor 64 Alfacell proprietary ribonuclease 64 nucleoside analogues 64 temsirolimus 64 Lenalidomide 64 Sym# 64 catheter occlusion 64 HCV protease inhibitors 64 Xyfid TM 64 cytoreductive nephrectomy 64 Laquinimod 64 Syncria R 64 MEK inhibitor 64 XYOTAX TM 64 overactive bladder OAB 64 TKB# 64 recurrent glioma 64 pain palliation 64 Afatinib 64 TLK# 64 Deforolimus 64 CIMZIA TM 64 FOLFOX6 chemotherapy regimen 64 Tocilizumab 64 Xeloda ® 64 PROSTVAC VF 64 Zenvia ™ 64 Bucindolol 64 diabetic neuropathic pain 64 anti amnesic 64 AA amyloidosis 64 prescribed proton pump 64 non nucleoside inhibitor 64 hypoparathyroidism 64 HNSCC 64 non thiazolidinedione TZD 64 Ofatumumab 64 EGFR TKI 64 lapatinib Tykerb 64 Elvitegravir 64 Onconase 64 delta gamma agonist 64 glioblastoma multiforme GBM 64 epithelial ovarian cancer 64 Lenocta 64 neuroendocrine cancers 64 primary hyperparathyroidism 64 Pharmacokinetics PK 64 HER2 overexpression 64 metastatic ocular 64 JAK2 Inhibitor 64 FASLODEX 64 CANCIDAS 64 Acute Myeloid Leukemia AML 64 cathepsin K inhibitor 64 lorvotuzumab mertansine 64 abnormal p# 64 psoriatic arthritis PsA 64 Granulocyte Colony Stimulating Factor 64 bladder ovarian 64 IMiDs 64 minimally symptomatic metastatic castrate 64 Ataluren 64 ORENCIA ® 64 IL# PE#QQR 64 class mGluR5 inhibitor 64 Fludarabine 64 hormone refractory metastatic prostate 64 gastrointestinal stromal tumor GIST 64 2 methoxyestradiol 64 tyrosine kinase inhibitor TKI 64 relapsing multiple sclerosis 64 CR# vcMMAE 64 SinuNase ™ 64 Severe Sepsis 64 MT#/MEDI-# 64 imatinib resistant 64 TNF alpha selectively neutralizing 64 methylnaltrexone bromide 64 generation antisense inhibitor 64 #I TM# 64 Plus Ribavirin 64 Xanafide 64 Solorel TM 64 complement inhibitor eculizumab 64 Phase #/#a trial 64 Initiates Enrollment 64 Neoadjuvant 64 Hypoactive Sexual Desire Disorder 64 novel therapeutic antibodies 64 NS5B polymerase 64 immunomodulating 64 lung pancreatic 64 huN# DM1 64 Flu Cy 64 antiretroviral naïve 64 antiandrogens 64 chemoresistant 64 PCa 64 CYP#A# substrate 64 BENLYSTA ® 64 registrational Phase 64 DELATESTRYL R 64 TroVax ® 64 Tavocept 64 MyVax R 64 ALVESCO R 64 genomic biomarker 64 IGF IR 64 GMX# 64 alefacept 64 Iluvien TM 64 Annamycin 64 chronic HCV 64 advanced epithelial ovarian 64 ADPKD 64 investigational therapies 64 ulimorelin 64 INCB# [001] 64 esophageal gastric 64 LHRH antagonists 64 olaparib 64 Kuvan R 64 systemic juvenile idiopathic 64 regorafenib 64 lupus nephritis 64 Immunotherapeutic 63 Cell Lymphoma 63 entinostat 63 primary hypercholesterolemia 63 pancreatic neuroendocrine tumors 63 secondary hypogonadism 63 Prostate AdenoCarcinoma Treatment 63 VEGF inhibitors 63 Telintra 63 VA# [002] 63 TG# [003] 63 symptomatic benign prostatic 63 tumor necrosis 63 compound AEZS 63 ILUVIEN ® 63 Pyridorin 63 R bisoprolol Euthyrox 63 Allovectin 7 R 63 CIMZIA ™ 63 LHRH analogues 63 Preclinical studies suggest 63 vemurafenib 63 Entereg R 63 histone deacetylase inhibitor 63 HuMax EGFr 63 adriamycin 63 itraconazole Sporanox 63 DAVANAT 63 Phase Ib IIa 63 either acutely decompensated 63 delay bone metastases 63 Idiopathic Pulmonary Fibrosis 63 mitogen activated ERK kinase 63 plasma kallikrein inhibitor 63 investigational pharmacologically unique 63 axitinib 63 cisplatin resistant 63 developing Bicifadine serotonin 63 NASH Huntington 63 Exelixis XL# 63 peritoneal carcinomatosis 63 oral ridaforolimus 63 Phase Ib II 63 denileukin diftitox 63 adult chronic ITP 63 vascular disrupting agent 63 Sezary syndrome 63 RNAi therapeutic targeting 63 anthracycline containing 63 anticancer compound 63 oral Janus kinase 63 Clofarabine 63 humanized monoclonal 63 aflibercept VEGF Trap 63 smoldering multiple myeloma 63 Bronchiectasis 63 gemcitabine Gemzar 63 compound ITMN 63 Chronic Hepatitis C 63 acute myelogenous leukemia AML 63 lucinactant 63 investigational antiplatelet agent 63 Relapsing Remitting Multiple Sclerosis 63 Troxatyl 63 targeted antifolate 63 oral proteasome inhibitor 63 immunomodulatory therapy 63 recurrent metastatic ovarian cancer 63 gemcitabine carboplatin 63 abacavir lamivudine 63 potent antiproliferative 63 zanolimumab 63 Complicated Skin 63 antifibrotic 63 Protein Kinase C 63 Avanafil 63 intravesical infusion therapy 63 highly selective inhibitor 63 paclitaxel cisplatin 63 agalsidase alfa 63 vinorelbine tartrate 63 castration resistant hormone refractory 63 Cethromycin 63 pralatrexate injection folate analogue 63 PEG interferon 63 bexarotene 63 unstable angina UA 63 RhuDex R 63 Actimmune ® 63 NU# direct 63 motesanib 63 vapreotide acetate 63 ATL# [001] 63 terlipressin 63 advanced hepatocellular carcinoma 63 enzastaurin 63 rhIGF-I/rhIGFBP-3 63 EGFR inhibitors 63 accumulate preferentially 63 benign prostatic hypertrophy 63 Friedreich Ataxia FRDA 63 thymalfasin 63 LibiGel ® 63 EGFr humanized monoclonal antibody 63 ARRY # 63 XL# anticancer compounds 63 neratinib 63 de novo kidney transplant 63 overactive bladder syndrome 63 Kinoid 63 metastatic HRPC 63 stage IIIB IV 63 LEUKINE 63 chronic HBV 63 mCRC patients 63 Pegylated Interferon 63 idiopathic thrombocytopenic purpura ITP 63 CDK inhibitor 63 INS# [001] 63 HCV SPRINT 63 resistant ovarian cancer 63 mertansine 63 pancreatic prostate 63 RhuDex TM 63 colorectal liver metastases 63 topical gel formulation 63 Refractory Hodgkin Lymphoma 63 Rindopepimut 63 BCR ABL inhibitors 63 LymphoStat B TM 63 pegfilgrastim 63 STRIDE PD 63 Neulasta ® 63 signal transduction inhibitors 63 Rebif ® 63 administered intranasally 63 colorectal bladder 63 Tarceva TM 63 SPC# [001] 63 SNT-MC#/idebenone 63 INVANZ 63 plus dacarbazine 63 Melphalan 63 XL# XL# XL# 63 Androxal ® 63 CD# CEA 63 alpha folate receptor 63 Pimavanserin 63 miconazole Lauriad ® 63 Crofelemer budesonide foam 63 Glioblastoma Multiforme 63 dexpramipexole 63 personalized immunotherapy 63 Radiation Therapy SIRT 63 reslizumab 63 vWD 63 Aurexis 63 AVODART 63 Leukemias 63 talactoferrin 63 pegylated liposomal doxorubicin 63 Carcinoid tumors 63 clinically localized prostate 63 HMG CoA reductase inhibitors 63 beta estradiol 63 JAK#/JAK# 63 vaginal candidiasis 63 virus HCV infection 63 Sprycel dasatinib 63 SERMs 63 diabetic macular edema DME 63 OvaRex ® MAb 63 ANCHOR trial 63 hepatocellular carcinoma HCC 63 Ambrisentan 63 antiangiogenesis therapies 63 Quinamed 63 sapropterin dihydrochloride 63 desvenlafaxine succinate 63 Alocrest 63 nilotinib Tasigna 63 paclitaxel Taxol ® 63 Copegus R 63 plus DOXIL 63 YONDELIS R 63 PROVENGE ® 63 Imatinib mesylate 63 treatmentof 63 AzaSite Plus 63 atherothrombotic events 63 IV NSCLC 63 generation PNP inhibitor 63 octreotide implant 63 PAOD 63 Stage IIB 63 davunetide intranasal AL 63 oral antidiabetic medication 63 transplantation HCT 63 myeloid metaplasia 63 Initiate Phase 63 bone metastasis 63 Omacetaxine mepesuccinate 63 Xeloda capecitabine 63 nucleotide analogue 63 occlusion CRVO 63 oral candidiasis 63 chemopreventive agent 63 Pivotal Trial 63 ara C 63 isoform selective 63 seminoma 63 vinca alkaloids 63 MPS IVA 63 Dalbavancin 63 Mantle Cell Lymphoma 63 Lixivaptan 63 urothelial bladder cancer 63 HGPIN 63 nucleoside analogue 63 NOX E# 63 decitabine 63 nonnucleoside reverse transcriptase inhibitors 63 trastuzumab DM1 63 Haptoglobin 63 Benign Prostatic Hyperplasia 63 Trastuzumab 63 ON #.Na 63 IMC A# 63 delivered RNAi therapeutic 63 Zybrestat 63 AVONEX ® 63 TBC# 63 hereditary deficiency 63 Chronic Heart Failure 63 non resectable 63 selective angiogenic kinase inhibitor 63 Gefitinib 63 pancreatic NET 63 trabectedin 63 Symadex 63 ARIKACE ™ 63 HER2 positive cancers 63 BRAF inhibitor 63 agonistic human 63 ONCONASE R 63 ENMD # 63 Myelodysplastic syndromes MDS 63 Vascular Disrupting Agent 63 Aviptadil 63 Akt inhibitor 63 Chemophase 63 PLX MS 63 pegylated interferon alpha 63 transarterial 63 Vicriviroc 63 chronic periodontitis 63 CINTREDEKIN BESUDOTOX 63 KRAS mutation 63 Alessandro Riva 63 pouchitis 63 Renal Cell Carcinoma RCC 63 rNAPc2 63 N acetylgalactosamine 6 63 allogeneic hematopoietic stem cell 63 T2DM 63 nab paclitaxel 63 neoadjuvant 63 uric acid lowering 63 plus COPEGUS 63 lenalidomide dexamethasone 63 ribavirin RBV 63 trastuzumab DM1 T DM1 63 Campath ®